185 filings
Page 7 of 10
8-K
a08i4 qmaa
3 Jun 20
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
7:26am
8-K
2xkib
3 Jun 20
Regulation FD Disclosure
7:25am
8-K
zsdobtuxh21h 27
6 Apr 20
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
4:23pm
8-K
vrgl w1eaz5
15 Jan 20
Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
4:01pm
8-K
fzecu zemt
10 Jan 20
Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
8:45am
8-K
5d6o8s
23 Dec 19
Departure of Directors or Certain Officers
5:03pm
8-K
g0r9j0bg0iy7ocq92uho
9 Dec 19
Departure of Directors or Certain Officers
5:02pm
8-K
dcr1s ml0
18 Nov 19
Replimune Announces Proposed Public Offering
8:02am
424B5
1k32a r1zp9ug
18 Nov 19
Prospectus supplement for primary offering
7:40am
FWP
idxjxx3zughkryc
13 Nov 19
Free writing prospectus
9:45pm
424B5
qo8lpb 10930ip
12 Nov 19
Prospectus supplement for primary offering
5:30pm
8-K
ss83116
12 Nov 19
Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
9:23am
8-K
rzz49 55f0i
8 Nov 19
NNEXEXT-TGGENENERERAATITOIONNOONNCCOOLYLYTITCIC IMIMMMUUNNOOTHTHERERAAPPYY SITC Investor Event Presentation November 8th 2019
4:30pm
8-K
nhzfx8crdrhy8xp vcq7
15 Oct 19
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
8:24am
8-K
ivm9 00akgs
10 Sep 19
Amendments to Articles of Incorporation or Bylaws
4:00pm
EFFECT
e5uac e3bxs
16 Aug 19
Notice of effectiveness
12:15am
CORRESP
371m ezf8q85
15 Aug 19
Correspondence with SEC
12:00am
8-K
vz8tvstky4wslx7bpag2
14 Aug 19
Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
4:35pm